# Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT06972641** · PHASE2,PHASE3 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 126 (estimated)

## Conditions studied

- AML
- MDS

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Sorafenib (BAY-43-9006)，giritinib
- **DRUG:** Avastinib
- **DRUG:** Venetoclax;Selenisol

## Key facts

- **NCT ID:** NCT06972641
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-10
- **Primary completion:** 2030-03-31
- **Final completion:** 2030-03-31
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06972641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06972641, "Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06972641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*